摘要
抗程序性细胞死亡蛋白-1(PD-1)单克隆抗体在复发/难治性经典型霍奇金淋巴瘤(R/R cHL)患者中显示出高反应率。^(18)F-FDG PET/CT在淋巴瘤的诊断、分期和反应评估中发挥重要作用。本文综述淋巴瘤治疗反应评估标准的衍变,以及^(18)F-FDG PET/CT在评估R/R cHL免疫治疗早期反应中的应用进展。
Anti-programmed cell death protein-1(PD-1)monoclonal antibodies demonstrate high response rates in patients with relapsed/refractory classical Hodgkin lymphoma(R/R cHL).18 F-FDG PET plays an important role in the diagnosis,staging and response assessment of lymphoma.This article reviews and summarizes the evolution of lymphoma treatment response evaluation criteria and the application of^(18)F-FDG PET/CT in the early response assessment of immunotherapy in patients with relapsed/refractory classic Hodgkin lymphoma.
作者
汤明
邹思娟
朱小华
TANG Ming;ZOU Sijuan;ZHU Xiaohua(Department of Nuclear Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处
《中国医学影像学杂志》
CSCD
北大核心
2021年第8期846-850,860,共6页
Chinese Journal of Medical Imaging
基金
国家自然科学基金(91959119)。
